Corpus ID: 17491917

Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.

@article{McCaffery1996ImmunizationOM,
  title={Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.},
  author={M. McCaffery and T. J. Yao and L. Williams and P. Livingston and A. Houghton and P. Chapman},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={1996},
  volume={2 4},
  pages={
          679-86
        }
}
  • M. McCaffery, T. J. Yao, +3 authors P. Chapman
  • Published 1996
  • Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • Previous attempts to immunize melanoma patients against GD3 ganglioside have been unsuccessful because of the poor immunogenicity of GD3. BEC2, an anti-idiotypic monoclonal antibody that mimics GD3, can induce anti-GD3 IgG in rabbits. Since clinical trials with BEC2 in melanoma patients demonstrated that BEC2 alone is not highly immunogenic, we have carried out sequential clinical trials exploring the use of two immunological adjuvants, BCG and QS21, administered with BEC2. Melanoma patients… CONTINUE READING
    Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.
    • 91
    • Highly Influenced
    • PDF

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 31 REFERENCES
    Immunogenicity of melanoma‐associated gangliosides in cancer patients
    • 178
    BCG immunotherapy in stage I melanoma patients
    • 10